-
Product Insights
NewHypoxia Inducible Factor 2 – Drugs In Development, 2024
The Hypoxia Inducible Factor 2 pipeline drugs market research report outlays comprehensive information on the Hypoxia Inducible Factor 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Cardiovascular, Genetic Disorders, and Undisclosed which include indications of Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Pulmonary Arterial Hypertension, Von Hippel-Lindau Syndrome, and Unspecified Rare Disease. It also reviews...
-
Product Insights
NewNitric Oxide Synthase Inducible – Drugs In Development, 2024
The Nitric Oxide Synthase Inducible pipeline drugs market research report outlays comprehensive information on the Nitric Oxide Synthase Inducible targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Respiratory, Immunology, Musculoskeletal Disorders, and Oncology which include indications of Acute Respiratory Distress Syndrome, Idiopathic Pulmonary Fibrosis, Inflammation, Systemic Sclerosis (Scleroderma), Musculoskeletal Disorders, Arthritis, Brain Cancer, and Malignant Glioma. It...
-
Product Insights
NewInducible T Cell Costimulator – Drugs In Development, 2024
The Inducible T Cell Costimulator pipeline drugs market research report outlays comprehensive information on the Inducible T Cell Costimulator targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Metabolic Disorders, and Ophthalmology which include indications of Non-Small Cell Lung Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Systemic Lupus Erythematosus, Type 1 Diabetes (Juvenile Diabetes), and...
-
Product Insights
NewHypoxia Inducible Factor 1 Alpha – Drugs In Development, 2024
The Hypoxia Inducible Factor 1 Alpha pipeline drugs market research report outlays comprehensive information on the Hypoxia Inducible Factor 1 Alpha targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Ophthalmology, Gastrointestinal, and Dermatology which include indications of Oncology, Melanoma, Ophthalmology, Glaucoma, Oral Mucositis, Liver Failure (Hepatic Insufficiency), Diabetic Foot Ulcers, and Dermatitis (Eczema). It also reviews...
-
Product Insights
NewInduced Myeloid Leukemia Cell Differentiation Protein Mcl 1 – Drugs In Development, 2024
The Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 pipeline drugs market research report outlays comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, and Infectious Disease which include indications of Oncology, Solid Tumor, and Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. It also reviews key players...
-
Product Insights
NewInterferon Induced Double Stranded RNA Activated Protein Kinase – Drugs In Development, 2024
The Interferon Induced Double Stranded RNA Activated Protein Kinase pipeline drugs market research report outlays comprehensive information on the Interferon Induced Double Stranded RNA Activated Protein Kinase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Infectious Disease, Oncology, and Undisclosed which include indications of Alzheimer's Disease, Dementia, Unspecified Influenza Virus Infections, Breast Cancer, Prostate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mesdopetam in Drug-Induced Dyskinesia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mesdopetam in Drug-Induced Dyskinesia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mesdopetam in Drug-Induced Dyskinesia Drug Details: Mesdopetam (IRL-790) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HM-01 in Chemotherapy Induced Peripheral Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HM-01 in Chemotherapy Induced Peripheral Neuropathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HM-01 in Chemotherapy Induced Peripheral Neuropathy Drug Details: HM-01...
-
Product Insights
Likelihood of Approval Analysis for Chemotherapy Induced Neutropenia
Overview How likely is it that the drugs in Chemotherapy Induced Neutropenia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Chemotherapy Induced Neutropenia Overview Chemotherapy-induced neutropenia is a very common side...
-
Product Insights
Likelihood of Approval Analysis for Chemotherapy Induced Nausea and Vomiting
Overview How likely is it that the drugs in Chemotherapy Induced Nausea and Vomiting will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Chemotherapy Induced Nausea and Vomiting Overview Chemotherapy-induced nausea and...